Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genor Biopharma Holdings Limited ( (HK:6998) ) has provided an update.
Genor Biopharma Holdings Limited announced the inclusion of its drug Lerociclib (GB491) in China’s National Reimbursement Drug List, effective January 2026. This inclusion is expected to enhance patient access, reduce financial burdens, and accelerate the drug’s commercialization and market penetration, thereby increasing returns for innovation.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. The company focuses on developing innovative therapies, particularly in the field of oncology, with products such as Lerociclib, a CDK4/6 inhibitor for breast cancer treatment.
YTD Price Performance: 116.76%
Average Trading Volume: 1,139,768
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.97B
For a thorough assessment of 6998 stock, go to TipRanks’ Stock Analysis page.